Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in their shareholdings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary Shares by various directors and senior managers on October 3, 2013. These acquisitions were executed at a price of 1,569.68 pence per share through the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of share purchases.
Key Facts for Investor Verification
- Transaction Date: October 3, 2013.
- Share Price: 1,569.68 pence per Ordinary Share.
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Participants: Includes Sir Andrew Witty (27 shares), Mr. S M Bicknell (40 shares), Mr. D S Redfern (40 shares), Ms. C Thomas (40 shares), and several other directors acquiring between 2 and 34 shares.
- Notification Date: October 4, 2013.